Recombinant Human CD39 protein (GST tag N-Terminus)
Be the first to review this product! Submit a review
|
(0 Publication)
Recombinant Human CD39 protein (GST tag N-Terminus) is a Human Full Length protein, in the 1 to 510 aa range, expressed in Wheat germ, suitable for SDS-PAGE, ELISA, WB.
View Alternative Names
CD39, ENTPD1, Ectonucleoside triphosphate diphosphohydrolase 1, ATP diphosphohydrolase, Ecto-ATP diphosphohydrolase 1, Ecto-apyrase, Lymphoid cell activation antigen, Nucleoside triphosphate diphosphohydrolase 1, ATP-DPH, ATPDase, Ecto-ATPDase 1, Ecto-ATPase 1, NTPDase1
- SDS-PAGE
Unknown
SDS-PAGE - Recombinant Human CD39 protein (GST tag N-Terminus) (AB114445)
ab114445 analysed on a 12.5% SDS-PAGE gel stained with Coomassie Blue.
Reactivity data
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Specifications
Form
Liquid
General info
Function
Catalyzes the hydrolysis of nucleoside triphosphates (NTPs) and diphosphates (NDPs) (Probable) (PubMed : 8529670, PubMed : 8626624, PubMed : 8955160, PubMed : 8996251). The enzyme sequentially removes phosphate groups in two successive steps, converting NTPs to nucleoside monophosphates (NMPs) via NDP intermediates (Probable) (PubMed : 8529670, PubMed : 8626624, PubMed : 8955160, PubMed : 8996251). This activity contributes to the regulation of extracellular levels of nucleotides (Probable) (PubMed : 8529670, PubMed : 8626624, PubMed : 8955160, PubMed : 8996251). By hydrolyzing proinflammatory ATP and platelet-activating ADP to AMP, it blocks platelet aggregation and supports blood flow (PubMed : 8955160, PubMed : 8996251).
Sequence similarities
Belongs to the GDA1/CD39 NTPase family.
Post-translational modifications
N-glycosylated.. The N-terminus is blocked.. Palmitoylated on Cys-13; which is required for caveola targeting.
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com